Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.
复制标题
DOI：
10.3233/jpd-130189
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Leverenz JB
中科院分区：
文献类型：
--
作者：
Cholerton BA;Zabetian CP;Quinn JF;Chung KA;Peterson A;Espay AJ;Revilla FJ;Devoto J;Watson GS;Hu SC;Edwards KL;Montine TJ;Leverenz JB
帕金森病（PD）患者中有相当大比例的人患有或预计会出现伴随的认知障碍，这强调了需要大型，特征良好的参与者队列作为研究PD患者认知下降的原因，表现和潜在治疗方法的基础。通过获得高质量的纵向临床、神经心理学和经验证的生物标志物数据，建立一个多中心临床核心，在认知和临床上表征PD患者。619名特发性PD患者（68.0 ± 9.1岁，诊断后7.1 ± 6.2年，70%为男性）入组太平洋西北尤德尔中心（PANUC），该中心是Morris K. Udall帕金森病研究卓越中心，临床联盟，并进行了全面的临床和神经心理学评估。参与者在诊断共识会议上被诊断为无认知障碍（PD-NCI），轻度认知障碍（PD-MCI）或痴呆（PDD）。总体样本中有很大比例在基线时被诊断为认知障碍：PDD为22%，PD-MCI为59%。尽管受教育程度较高，但男性的认知障碍发生率高于女性（87%对68%，p<0.0001）。大多数患者在诊断时年龄超过50岁，病程超过10年，有认知障碍或痴呆。PANUC临床联盟是一个具有良好临床和认知特征的PD患者队列。基线队列特征表明样本中认知障碍的发生率较高，以及认知诊断方面的潜在性别差异。PANUC临床联盟可获得生物标志物、遗传学和尸检数据，为与PD认知障碍相关的详细研究提供了良好的基础。
The substantial proportion of individuals with Parkinson’s disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson’s Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p<0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.